PDX Model

MSK-LX285

MSK-LX285

Sex: Male

Histology: Adenocarcinoma

Key Mutations: EGFR L858R, EGFR T790M, EGFR Amplified

Molecular Characteristics: MSK-IMPACT

Matched Normal: Yes

Treatment: erlotinib

Site: Lung

Paired: No

Comments: erlotinib resistant

Licensing Information: Corporations and other for-profit entities may nonexclusively license Memorial Sloan Kettering’s tangible materials for research or commercial purposes.

MSK Office of Technology Development Contact: Alexandra Buga, MS, MBA, Licensing Associate, T: 646-888-1078, e-mail: bugaa@mskcc.org.

Stage of Development

Ready to use

Indications